BRCA1_variant,Nucleotide_change,Amino_acid_change,Full_length_His_BRCA1_HEK293FT_percent,Fusion_protein_DBD_BRCT_HEK293FT_percent,HDR_assay_His_BRCA1_HeLa_DR_GFP_percent,TA_assay_DBD_BRCT_HEK293_percent,Results_in_functional_assays_this_study
VUSs,,,,,,,
,c.4315C>T,p.Leu1439Phe,64±12,99±9,19.4±2.9,167±11,Reduced HRR and normal TA
,c.4603G>A,p.Glu1535Lys,65±12,84±30,19.6±2.4,97±6,Reduced HRR and normal TA
,c.4884G>A,p.Met1628Ile,48±12,76±6,19.9±1.8,128±13,Reduced HRR and normal TA
,c.5002T>C,p.Phe1668Leu,35±13,15±2,19.6±2.3,81±6,Reduced HRR and normal TA
,c.5101C>A,p.Leu1701Met,47±8,45±10,19.4±2.7,107±9,Reduced HRR and normal TA
,c.5123C>T,p.Ala1708Val,5±3,3±1,16.0±1.7,16±2,Reduced HRR and reduced TA
,c.5125G>A,p.Gly1709Arg,2±3,7±4,22.4±1.3,43±7,Reduced HRR and normal TA
,c.5131A>C,p.Lys1711Gln,13±7,12±6,17.8±2.1,42±10,Reduced HRR and normal TA
,c.5153G>C,p.Trp1718Ser,1±0,1±0,21.4±1.8,2±1,Reduced HRR and reduced TA
,c.5245C>G,p.Pro1749Ala,40±10,23±5,101.3±2.7,88±16,No alterations
,c.5504G>A,p.Arg1835Gln,60±32,59±11,21.4±2.1,108±10,Reduced HRR and normal TA
Benign_control_variants,,,,,,,
,WT,WT,100±13,100±36,100,100±3,
,c.4956G>A,p.Met1652Ile,58±15,23±3,92.6±2.9,97±11,
,c.5411T>A,p.Val1804Asp,80±26,41±6,99.6±1.8,95±14,
Pathogenic_control_variants,,,,,,,
,c.5095C>T,p.Arg1699Trp,21±14,3±2,25.1±0.8,16±9,
,c.5513T>G,p.Val1838Gly,6±8,1±2,21.9±4.0,1±0,